Saturday, November 21, 2026

Pacific Biosciences Of California Stock Impressive Rise Before The Weekend, Outperforms Market

ViaNews Editorial Team

December 15, 2023

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Pacific Biosciences Of California Stock  Impressive Rise Before The Weekend, Outperforms Market

(VIANEWS) - The NASDAQ ended the session with Pacific Biosciences of California rising 11.34% to $9.86 on Friday, following the last session's upward trend. NASDAQ jumped 0.19% to $14,761.56, after five consecutive sessions in a row of gains, on what was a somewhat up trend trading session today.

Pacific Biosciences of California's last close was $8.86, 39.11% under its 52-week high of $14.55.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Earnings Per Share

As for profitability, Pacific Biosciences of California has a trailing twelve months EPS of $-1.27.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -44.46%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 72.4%, now sitting on 169.52M for the twelve trailing months.

Sales Growth

Pacific Biosciences of California's sales growth is 104% for the ongoing quarter and 59.3% for the next.

Yearly Top and Bottom Value

Pacific Biosciences of California's stock is valued at $9.86 at 02:15 EST, way below its 52-week high of $14.55 and way above its 52-week low of $5.74.

More news about Pacific Biosciences of California (PACB).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 15 Dec 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.